In line with these findings, higher levels of sFlt-1 and AT1 autoantibodies, both markers of preeclampsia, were observed in COVID-19 positive mothers [50] and in cases of patients developing preeclampsia-like syndrome among women with severe COVID-19 manifestation [53]. This evidence concerns the gene AGTR1 and COVID-19.